Emergent BioSolutions Inc. (NYSE:EBS) Stock Position Cut by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. lessened its stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 50.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 383,043 shares of the biopharmaceutical company's stock after selling 388,095 shares during the period. D. E. Shaw & Co. Inc. owned 0.71% of Emergent BioSolutions worth $3,662,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Covestor Ltd grew its position in Emergent BioSolutions by 5,458.5% in the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 2,893 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in Emergent BioSolutions in the 4th quarter valued at about $63,000. E Fund Management Co. Ltd. bought a new position in Emergent BioSolutions in the 4th quarter valued at about $98,000. EP Wealth Advisors LLC bought a new position in Emergent BioSolutions in the 4th quarter valued at about $110,000. Finally, Alpine Global Management LLC bought a new position in Emergent BioSolutions in the 4th quarter valued at about $112,000. Institutional investors own 78.40% of the company's stock.

Insider Activity

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the transaction, the director now directly owns 101,100 shares in the company, valued at $589,413. This trade represents a 25.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 1.20% of the company's stock.

Wall Street Analysts Forecast Growth

EBS has been the subject of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday, April 1st. StockNews.com lowered shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research report on Wednesday, March 5th.

Emergent BioSolutions Stock Performance

NYSE:EBS opened at $6.66 on Monday. Emergent BioSolutions Inc. has a twelve month low of $4.02 and a twelve month high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The company has a 50-day moving average of $5.16 and a 200-day moving average of $7.78. The firm has a market cap of $361.22 million, a price-to-earnings ratio of -1.62 and a beta of 2.09.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.22. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The company had revenue of $222.20 million during the quarter, compared to analyst estimates of $218.50 million. Analysts forecast that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Emergent BioSolutions declared that its Board of Directors has approved a stock repurchase program on Monday, March 31st that permits the company to repurchase $50.00 million in shares. This repurchase authorization permits the biopharmaceutical company to purchase up to 19% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.